TGTX
TG Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.65B
P/E Ratio
12.77
EPS
$2.77
Beta
1.75
52W High
$46.48
52W Low
$25.28
50-Day MA
$31.72
200-Day MA
$31.95
Dividend Yield
—
Profit Margin
72.60%
Forward P/E
37.59
PEG Ratio
1.61
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | $616.29M |
| Gross Profit (TTM) | $515.57M |
| EBITDA | $123.38M |
| Operating Margin | 26.20% |
| Return on Equity | 102.80% |
| Return on Assets | 9.39% |
| Revenue/Share (TTM) | $4.27 |
| Book Value | $4.52 |
| Price-to-Book | 8.72 |
| Price-to-Sales (TTM) | 9.17 |
| EV/Revenue | 9.35 |
| EV/EBITDA | 42.88 |
| Quarterly Earnings Growth (YoY) | -6.10% |
| Quarterly Revenue Growth (YoY) | 78.00% |
| Shares Outstanding | $159.69M |
| Float | $140.95M |
| % Insiders | 7.19% |
| % Institutions | 66.40% |
Historical Volatility
HV 10-Day
50.79%
HV 20-Day
42.07%
HV 30-Day
48.09%
HV 60-Day
43.82%
HV Rank
71.0%
Volatility is currently expanding
Analyst Ratings
Consensus ($44.57 target)
1
Strong Buy6
Buy1
Hold1
Strong SellData last updated: 4/28/2026